Nexalin Technology (NXL) Return on Capital Employed Growth (1y) (2023 - 2026)
Nexalin Technology (NXL) Return on Capital Employed Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -286.00 |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 6,388.00 |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 39.00 |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 200.00 |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -41.00 |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 879.00 |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -2,494.00 |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 632.00 |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 216.00 |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 | -27,119.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27,119.00 |
| Mar 31, 2026 | 3,781.00 |
| Dec 31, 2025 | -2,519.00 |
| Sep 30, 2025 | 4,774.00 |
| Jun 30, 2025 | 10,448.00 |
| Mar 31, 2025 | -7,126.00 |
| Dec 31, 2024 | -2,703.00 |
| Sep 30, 2024 | -7,626.00 |
| Jun 30, 2024 | -26,163.00 |
| Mar 31, 2024 | -17,899.00 |
| Dec 31, 2023 | -12,706.00 |